Irinotecan (CPT-11) - Moligand™, 10mM in DMSO , Inhibitor of DNA topoisomerase I, CAS No.97682-44-5, Inhibitor of DNA topoisomerase I

CAS: 97682-44-5 Cat. No.: I408152 Peso molecular: 586.68 Número EC: 691-567-9

GRADE & PURITY Moligand™, 10mM in DMSO

Synonyms

(+)-Irinotecan | (4S)​-​4,​11-​diethyl-​3,​4,​12,​14-​tetrahydro-​4-​hydroxy-​3,​14-​dioxo-​1H-​pyrano[3',​4':6,​7]​indolizino[1,​2-​b]​quinolin-​9-​yl-[1,​4'-​bipiperidine]​-​1'-​carboxylic acid

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Descripción general

Information

Irinotecan (CPT-11, (+)-Irinotecan) is a topoisomerase I inhibitor for LoVo cells and HT-29 cells with IC50 of 15.8 μM and 5.17 μM, respectively.
In vitro

Irinotecan is activated to SN-38 by carboxylesterases to become able to interact with its target, topoisomerase I. Irinotecan induces similar amounts of cleavable complexes at its IC50 in LoVo cells and HT-29 cell lines. SN-38 induces a concentration-dependent formation of cleavable complexes, which is not significantly different in LoVo cells and HT-29 cell lines. Cell accumulation of Irinotecan is markedly different, reaching consistently higher levels in HT-29 cells than in LoVo cells. The lactone E-ring of Irinotecan and SN-38 hydrolyses reversibly in aqueous solutions, and the interconversion between the lactone and carboxylate forms is dependent on pH and temperature. Liver is primarily responsible for the activation of Irinotecan to SN-38. At equal concentrations of Irinotecan and SN-38 glucuronide, the rate of beta-glucuronidase-mediated SN-38 production is higher than that formed from Irinotecan in both tumour and normal tissue. Irinotecan is also converted to SN-38 in intestines, plasma and tumor tissues. Irinotecan is significantly more active in SCLC than in NSCLC cell lines, whereas no significant difference between histological types is observed with SN-38.

In vivo

In COLO 320 xenografts, Irinotecan induces a maximum growth inhibition of 92%. A single dose of Irinotecan significantly increases amounts of topoisomerase I covalently bound to DNA in stomach, duodenum, colon and liver. Concomitantly, the Irinotecan-treated group shows significantly higher amounts of DNA strand breaks in colon mucosa cells compared to the control group.
Cell Data

cell lines：

Concentrations：0 μM -100 μM

Incubation Time：48 hours

Powder Purity:≥99%

Specifications

Sinónimos

(+)-Irinotecan | (4S)​-​4, ​11-​diethyl-​3, ​4, ​12, ​14-​tetrahydro-​4-​hydroxy-​3, ​14-​dioxo-​1H-​pyrano[3', ​4':6, ​7]​indolizino[1, ​2-​b]​quinolin-​9-​yl-[1, ​4'-​bipiperidine]​-​1'-​carboxylic acid

Especificaciones y pureza

Moligand™, 10mM in DMSO

Mecanismos bioquímicos y fisiológicos

Irinotecan (CPT-11, (+)-Irinotecan) is a topoisomerase I inhibitor for LoVo cells and HT-29 cells with IC50 of 15.8 μM and 5.17 μM, respectively.

Condiciones de almacenamiento de almacenamiento

Store at -80°C

Enviado en

Dry ice packs + Cold packs

Este producto requiere envío en cadena de frío. Los servicios terrestres y otros servicios económicos no están disponibles.

Grado

Moligand™

Tipo de acción

INHIBITOR

Mecanismo de acción

Inhibitor of DNA topoisomerase I

Nombres e identificadores

• Isómeros SMILES: CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7
• Peso molecular: 586.68
• Reaxy-Rn: 4285693
• Reaxys-RN_link_address: https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=4285693&ln=

Objetivos asociados (humanos)

ACHE Tclin Acetylcholinesterase (1 Activities)

Discover Target: ACHE

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Propiedades químicas y físicas

• Solubilidad: Solubility (25°C) In vitro DMSO: 71 mg/mL (200.89 mM); Ethanol: 71 mg/mL (200.89 mM); Water: Insoluble

Referencias

1. Yaowei Guo, Jin Liu, Qinglin Tang, Cuicui Li, Yanying Zhang, Yao Wang, Yanxin Wang, Yupeng Bi, Christopher D. Snow, Matt J. Kipper, Laurence A. Belfiore, Jianguo Tang.  (2022)  Lanthanide (Eu3+/Tb3+)-Loaded γ-Cyclodextrin Nano-Aggregates for Smart Sensing of the Anticancer Drug Irinotecan.  INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES,  23  (12): (6597).  [PMID:35743042] [10.3390/ijms23126597]

2. Mengjing Zhao, Tianpeng Zhang, Fangjun Yu, Lianxia Guo, Baojian Wu.  (2018)  E4bp4 regulates carboxylesterase 2 enzymes through repression of the nuclear receptor Rev-erbα in mice.  BIOCHEMICAL PHARMACOLOGY,      [PMID:29653076] [10.1016/j.bcp.2018.04.005]

3. Yuan-yuan Zhai, Qiang Wang, Qi-yao Nong, Mei-yu Gao, Ying Zhang, Qin-wen Xiao, Yuan Tian, Zun-jian Zhang, Feng-guo Xu, Pei Zhang.  (2025)  Pitavastatin overcomes multi-drug resistance in CRC and NSCLC by targeting the NRP1-ZFX axis.  BIOCHEMICAL PHARMACOLOGY,      [PMID:40684995] [10.1016/j.bcp.2025.117183]

4. Lumei Dai, Shifang Wen, Yaling Chen, Xinchun Li, Bing Zhao, Xinyu You, Rongqiang Li, Bin Zhang.  (2025)  Self-assembled dual-target ibuprofen-irinotecan conjugate for colorectal cancer therapy.  BIOORGANIC & MEDICINAL CHEMISTRY,      [PMID:40850193] [10.1016/j.bmc.2025.118367]

5. Yifan Wu, Xiaoxia Gong, Jianzhong Shen, Kui Zhu.  (2023)  Postantibiotic leukocyte enhancement-mediated reduction of intracellular bacteria by macrophages.  Journal of Advanced Research,      [PMID:37290606] [10.1016/j.jare.2023.05.010]

6. Zhongcheng Yang, Zhijun Cao, Wenxin Wang, Ya Chen, Wanqiu Huang, Shixuan Jiao, Siliang Chen, Lianru Chen, Yuxia Liu, Jianming Mao, Luyong Zhang, Zheng Li.  (2023)  Design, synthesis, and biological evaluation studies of novel carboxylesterase 2 inhibitors for the treatment of irinotecan-induced delayed diarrhea.  BIOORGANIC CHEMISTRY,      [PMID:37300962] [10.1016/j.bioorg.2023.106625]

7. Lanhong Su, Wen Pan, Xiangxia Li, Xingyu Zhou, Xiaopeng Ma, Yuanzeng Min.  (2022)  Utilizing chemotherapy-induced tumor RNA nanoparticles to improve cancer chemoimmunotherapy.  Acta Biomaterialia,      [PMID:36563773] [10.1016/j.actbio.2022.12.039]

8. Lanhong Su, Yuhao Hao, Rui Li, Wen Pan, Xiaopeng Ma, Jianping Weng, Yuanzeng Min.  (2022)  Red blood cell-based vaccines for ameliorating cancer chemoimmunotherapy.  Acta Biomaterialia,      [PMID:36241013] [10.1016/j.actbio.2022.10.001]

9. Bo Lv, Ruijie Xu, Xinrui Xing, Chuyao Liao, Zunjian Zhang, Pei Zhang, Fengguo Xu.  (2022)  Discovery of Synergistic Drug Combinations for Colorectal Cancer Driven by Tumor Barcode Derived from Metabolomics “Big Data”.  Metabolites,  12  (6): (494).  [PMID:35736427] [10.3390/metabo12060494]

10. Jiao Yang Lu, Fu Rui Zhang, Xue Zhi Ding, Li Qiu Xia, Wei Tao Huang.  (2021)  Natural interface guiding cell: Directly using waste fish scales with rich micro/nano structures for control of cell behaviors.  APPLIED SURFACE SCIENCE,      [PMID:] [10.1016/j.apsusc.2021.152348]

11. Yue Shi-Jun, Qin Yi-Feng, Kang An, Tao Hui-Juan, Zhou Gui-Sheng, Chen Yan-Yan, Jiang Jian-Qin, Tang Yu-Ping, Duan Jin-Ao.  (2021)  Total Flavonoids of Glycyrrhiza uralensis Alleviates Irinotecan-Induced Colitis via Modification of Gut Microbiota and Fecal Metabolism.  Frontiers in Immunology,      [PMID:34025639] [10.3389/fimmu.2021.628358]

12. Dou-Dou XU, Xiao-Ying HOU, Ou WANG, Di WANG, Dan-Ting LI, Si-Yuan QIN, Bo LV, Xiao-Min DAI, Zun-Jian ZHANG, Jian-Bo WAN, Feng-Guo XU.  (2021)  A four-component combination derived from Huang-Qin Decoction significantly enhances anticancer activity of irinotecan.  Chinese Journal of Natural Medicines,      [PMID:33941341] [10.1016/S1875-5364(21)60034-1]

13. Ling Duan, Leijiao Deng, Dabin Wang, Shoucheng Ma, Chunmei Li, Da Zhao.  (2017)  Treatment mechanism of matrine in combination with irinotecan for colon cancer.  Oncology Letters,  14  (2): (2300-2304).  [PMID:28781667] [10.3892/ol.2017.6407]

14. Zhou Hongyan, Hu Dingxin, Zhao Xian, Qin Siyuan, Nong Qiyao, Tian Yuan, Zhang Zunjian, Dong Haijuan, Zhang Pei, Xu Fengguo.  (2024)  An optimal combination of four active components in Huangqin decoction for the synergistic sensitization of irinotecan against colorectal cancer.  Chinese Medicine,  19  (1): (1-12).  [PMID:38956673] [10.1186/s13020-024-00967-1]

15. Miaomiao Sun, Honghong Zhan, Xiaoliang Long, Ali M. Alsayed, Zhe Wang, Fancheng Meng, Guowei Wang, Jingxin Mao, Zhihua Liao, Min Chen.  (2024)  Dehydrocostus lactone alleviates irinotecan-induced intestinal mucositis by blocking TLR4/MD2 complex formation.  PHYTOMEDICINE,      [PMID:38518649] [10.1016/j.phymed.2024.155371]

16. Ya-Kun Zhang, Jian-Bo Tong, Hong-Yan Zhang, Mu-Xuan Luo, Zhi-Peng Qing, Cheng-Jian Tan.  (2025)  Design, synthesis, and antitumor evaluation of sophoridine derivatives as topoisomerase I inhibitors based on the topomer CoMFA model.  JOURNAL OF MOLECULAR STRUCTURE,      [PMID:] [10.1016/j.molstruc.2025.142005]

17. Yukun Zhong, Haining Li, Teng Jiang, Xueliang Mu, Munetoshi Seki, U Kei Cheang.  (2024)  Double-Layered Metal-Organic-Frameworks-Based Microswimmers for Adaptive Dual-Drug Anti-Cancer Therapy Using Artemisinin-Based Compounds.  Advanced Intelligent Systems,      [PMID:] [10.1002/aisy.202400244]

18. Zhao Xian, Xu Ruijie, Zhai Yuanyuan, Wang Yi, Zhang Yuxin, Tian Yuan, Xu Fengguo, Zhang Pei.  (2025)  Liposomal Vardenafil and Linagliptin Combined with Irinotecan for Synergistic Colorectal Cancer Therapy.  PHARMACEUTICAL RESEARCH,      [PMID:40473893] [10.1007/s11095-025-03876-6]

19. Shuiling Jin, Aifang Zhou, Qi Zhang, Di Zhao, Xintong Dong, Hong-Min Meng, Zhengquan Yu, Zhaohui Li.  (2025)  Engineered Cancer Cell Membrane-Functionalized Metal-Organic Frameworks for Irinotecan/Curcumin Codelivery in Colorectal Cancer: Enhanced Efficacy and Mitigated Toxicity.  International Journal of Nanomedicine,      [PMID:41287765] [10.2147/IJN.S558675]

20. Jiang Huan-guo, Zhan Zhi-kun, Tian Ling-min, Chen Yu-lian, Cai Mei-qun, Ge Guang-bo, Chen Xin, Wei Chuan-liang, Tang Lan.  (2026)  Oridonin exerts dual therapeutic effects in MASLD mice by integrating lipid homeostasis and drug bioactivation via the LXRα–CES1/CES2 pathway.  ACTA PHARMACOLOGICA SINICA,      [PMID:41639319] [10.1038/s41401-025-01737-x]

21. Yunhan Wang, Xinming Zhang, Fang Fang, Yunyan Chen, Yu Sun.  (2026)  NIR-activatable and colorectal cancer-targeted lipid polymer hybrid nanoparticles: Design and in vivo assessment.  JOURNAL OF DISPERSION SCIENCE AND TECHNOLOGY,      [PMID:] [10.1080/01932691.2026.2625044]

22. Yuanyuan Zhang, Mingyang Liu, Yifan Zhang, Fengxia Qin, Yuan Tian, Fengguo Xu, Yuxin Zhang, Pei Zhang.  (2026)  Nigakinone enhances FXR expression to synergize with irinotecan in suppressing colorectal cancer cells and xenografts.  BIOCHEMICAL PHARMACOLOGY,      [PMID:] [10.1016/j.bcp.2026.117904]

23. Nishtha Thakur, Pablo Mota-Santiago, Shuddhodana, Zaher Judeh.  (2026)  Interfacial Modulation of Cochleate Assembly via Cationic Surfactant Enables Enhanced Encapsulation of Water-Soluble Drugs.  COLLOIDS AND SURFACES B-BIOINTERFACES,      [PMID:] [10.1016/j.colsurfb.2026.115601]

24. Mengxi Xiang, Cheng Zhou, Chundong Yao, Jia Liu, Lin Wang, Zheng Wang.  (2026)  A Self-Assembled Irinotecan Nanomedicine Abrogates Steatohepatitis-Induced Liver Metastasis and Potentiates Antitumor Efficacy against Colorectal Cancer.  ACS Nano,      [PMID:] [10.1021/acsnano.6c00855]